Improving the Co-management of Moderate to Severe Pediatric and Adult Atopic Dermatitis in Primary Care and Specialty Settings

CE / CME

Improving the Co-management of Moderate to Severe Pediatric and Adult Atopic Dermatitis in Primary Care and Specialty Settings

Nurses/Nurse Practitioners: 1.00 NAPNAP contact hour, including 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: June 10, 2022

Expiration: June 09, 2023

Victoria Garcia-Albea
Victoria Garcia-Albea, PNP, DCNP
Tracey M. Piparo
Tracey M. Piparo, PA-C
Jonathan I. Silverberg
Jonathan I. Silverberg, MD, PhD, MPH

Pretest

Progress
1 2
Course Completed
1.
Which agent can be used in a 6-year-old patient with severe atopic dermatitis (AD) after an inadequate response to topical agents?
2.
Which agent would be the best choice for a patient who requests an oral therapy option for their moderate to severe AD (>30% body surface area [BSA])?
3.
In which of the following patients would a Janus kinase (JAK) inhibitor to treat AD be the most appropriate choice? A patient with a concomitant history of:
4.
How often do you currently step up to systemic therapy to manage AD refractory to basic management and topical corticosteroids?
5.
How often do you currently employ shared decision-making to help devise a treatment plan for patients with AD?
6.
How often do you currently initiate injectable agents to manage moderate to severe AD?